CLN — Celon Pharma SA Cashflow Statement
0.000.00%
Last trade - 00:00- PLN1.13bn
- PLN1.17bn
- PLN244.34m
Annual cashflow statement for Celon Pharma SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15.1 | -36.4 | -20 | -39.4 | -58 |
| Depreciation | |||||
| Non-Cash Items | 3.63 | -4.62 | -8.27 | -13.4 | 34.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 14.1 | -7.73 | -30.1 | -10.5 | -0.261 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 44 | -4.7 | -8.31 | -11.3 | 22 |
| Capital Expenditures | -41.4 | -33.9 | -32.8 | -22.8 | -32.9 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -79.7 | 2.43 | 11.2 | 15.3 | 13 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -121 | -31.5 | -21.6 | -7.49 | -19.8 |
| Financing Cash Flow Items | -14.3 | -1.5 | -2.62 | -2.19 | -1.41 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 181 | -28.7 | -20.6 | 13.3 | -9.76 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 104 | -64.9 | -50.5 | -5.51 | -7.55 |